emerg
infecti
diseas
major
threat
human
health
sever
viral
diseas
outbreak
occur
develop
region
health
condit
poor
increas
intern
travel
busi
possibl
eventu
transmit
infecti
virus
differ
countri
increas
effect
approach
prevent
viral
diseas
vaccin
howev
vaccin
current
avail
numer
viral
diseas
viruslik
particl
vlp
engin
vaccin
candid
studi
decad
vlp
construct
viral
protein
express
variou
express
system
promot
selfassembl
protein
structur
resembl
viru
particl
vlp
antigen
similar
nativ
viru
noninfecti
lack
key
viral
genet
materi
vlp
vaccin
attract
consider
research
interest
offer
sever
advantag
tradit
vaccin
studi
shown
vlp
vaccin
stimul
humor
cellular
immun
respons
may
offer
effect
antivir
protect
review
recent
develop
vlpbase
vaccin
sever
highli
virul
emerg
reemerg
infecti
diseas
infecti
agent
discuss
includ
rna
virus
differ
viru
famili
arenavirida
bunyavirida
calicivirida
coronavirida
filovirida
flavivirida
orthomyxovirida
paramyxovirida
togavirida
famili
increas
intern
travel
pathogen
transmiss
across
countri
increas
result
sever
pandem
especi
viral
diseas
outbreak
newli
identifi
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
report
saudi
arabia
de
groot
et
al
decemb
world
health
organ
notifi
laboratoryconfirm
merscov
infect
countri
least
death
march
ebola
viru
diseas
outbreak
report
west
africa
decemb
case
ebola
infect
report
includ
death
mortal
rate
pandem
caus
signific
mortal
econom
loss
thu
critic
prevent
spread
emerg
virus
vaccin
effect
prevent
viral
infect
howev
vaccin
develop
emerg
virus
face
sever
challeng
emerg
virus
caus
high
infect
mortal
therefor
maximum
level
biosafeti
lab
need
live
attenu
strain
inactiv
vaccin
adequ
safe
garciasastr
mena
second
outbreak
infect
emerg
viru
everi
second
matter
therefor
rapid
develop
engin
vaccin
requir
pandem
control
third
vaccin
influenza
viru
vaccin
effect
strain
mutat
antigen
drift
antigen
shift
influenza
viru
strain
differ
influenza
season
pandem
furthermor
viru
reproduc
autonom
vitro
vaccin
virus
produc
propag
virus
larg
quantiti
live
cell
suscept
organ
exampl
tradit
influenza
vaccin
manufactur
use
embryon
chicken
egg
viru
propag
howev
virus
still
cultur
cell
organ
outsid
natur
host
viruslik
particl
vlp
gener
viral
protein
selfassembl
structur
resembl
nativ
virion
antigen
nativ
viru
noninfecti
due
lack
viral
genet
materi
vlp
studi
vaccin
decad
first
vlpbase
vaccin
approv
us
fda
hbv
vaccin
heptavaxb
merck
zhao
et
al
recent
vlpbase
hpv
vaccin
merck
co
inc
glaxosmithklin
approv
us
fda
vaccin
produc
yeast
insect
cell
respect
rodriguezlima
et
al
advanc
biotechnolog
develop
vlp
vaccin
progress
greatli
vlp
offer
sever
advantag
vaccin
emerg
virus
first
safeti
consider
develop
vaccin
necessari
vlp
live
virus
thu
manufactur
process
offer
safer
environ
oper
second
vlp
display
major
antigen
elicit
strong
humor
cellular
immun
respons
potenc
vlp
stimul
immun
respons
significantli
enhanc
rel
inactiv
viral
particl
virus
evolv
differ
way
evad
host
immun
system
structur
nonstructur
protein
inhibit
immun
respons
especi
cellular
immun
respons
frazer
et
al
pukhalski
et
al
sarob
et
al
vlp
defici
protein
domain
inhibit
immun
respons
compar
individu
protein
peptid
vlp
better
immunogen
peptid
conform
vlp
similar
viru
inactiv
virus
due
highli
repetit
epitop
surfac
vlp
abl
induc
strong
b
cell
respons
et
al
vlp
also
intern
antigen
present
cell
activ
cell
elicit
sustain
specif
cytotox
lymphocyt
ctl
respons
wagner
et
al
chackerian
et
al
cox
et
al
cell
play
import
role
sustain
virusspecif
ctl
viru
infect
matloubian
et
al
sever
platform
produc
vlp
exist
bacteria
escherichia
coli
yeast
insect
cell
mammalian
cell
plant
express
system
vitro
cellfre
system
bacteri
express
system
first
system
use
produc
vlp
sever
commerci
vlp
vaccin
produc
use
system
one
hepat
e
viru
hev
vlp
xiamen
innovax
biotech
co
ltd
e
coli
express
system
econom
easytous
system
howev
system
lack
posttransl
modif
system
use
produc
simpl
vlp
nonenvelop
vlp
base
abil
viral
protein
compon
selfassembl
bacteri
host
express
yeast
system
commonli
use
vlp
vaccin
product
exampl
hbv
vaccin
engerixb
glaxosmithklin
hpv
vaccin
gardasil
merck
co
inc
yeast
system
offer
high
express
easi
scaleup
unlik
e
coli
system
provid
posttransl
modif
express
protein
howev
neither
e
coli
yeast
system
express
envelop
vlp
baculovirusinsect
cell
mammaliancel
system
show
complet
posttransl
modif
includ
glycosyl
better
system
express
complex
vlp
rodriguezlima
et
al
success
vlp
vaccin
produc
use
system
includ
hpv
vaccin
cervix
glaxosmithklin
hbv
vaccin
genhevac
b
aventi
system
expens
e
coli
yeast
downstream
process
difficult
plant
express
system
protein
assembl
posttransl
modif
similar
occur
mammalian
cell
product
system
costeffect
highli
scalabl
emerg
human
pathogen
singlestrand
rna
virus
summar
sever
vlp
vaccin
emerg
virus
includ
negativestrand
rna
virus
belong
famili
arenavirida
bunyavirida
filovirida
orthomyxovirida
paramyxovirida
positivestrand
rna
virus
famili
calicivirida
coronavirida
flavivirida
togavirida
virus
famili
human
pathogen
high
virul
lethal
vaccin
virus
urgent
need
pandem
control
arenavirus
pathogen
rodentstransmit
diseas
caus
sever
case
respons
hemorrhag
fever
oldston
lassa
fever
acut
viral
ill
report
west
africa
caus
lassa
fever
viru
lasv
member
arenavirida
famili
genom
lasv
consist
rna
segment
l
segment
encod
viral
nucleocapsid
protein
np
glycoprotein
wherea
l
segment
encod
viral
polymeras
l
ringfing
matrix
protein
z
gener
posttransl
cleavag
precursor
glycoprotein
gpc
serv
receptorbind
protein
transmembran
protein
oldston
z
protein
consid
main
drive
forc
viru
releas
z
protein
suffici
releas
viral
particl
strongli
membraneassoci
previou
find
show
express
z
protein
alon
suffici
releas
lipidenvelop
vlp
strecker
et
al
lasv
vlp
gener
use
mammalian
cell
express
system
express
major
immunolog
determin
glycoprotein
np
z
viral
protein
packag
particl
similar
nativ
virion
lasv
vlpimmun
mice
mount
substanti
high
igg
respons
individu
viral
protein
serum
lasvinfect
patient
react
vlp
branco
et
al
bunyavirida
famili
contain
genera
name
orthobunyaviru
phleboviru
nairoviru
hantaviru
tospoviru
tospovirus
plantinfect
virus
virus
genera
infect
anim
virus
famili
transmit
carri
arthropod
hantavirus
rodentborn
genom
bunyavirida
contain
negativesens
rna
segment
larg
segment
l
middl
segment
small
segment
bunyavirida
virion
nm
diamet
mostli
spheric
glycoprotein
spike
display
surfac
mostli
consist
heterodimer
gp
embed
viral
envelop
gp
gn
gc
interact
form
surfac
morpholog
unit
virion
matur
bud
golgi
complex
infect
cell
vlp
vaccin
develop
member
bunyavirida
famili
hantaviruslik
particl
obtain
coexpress
gn
gc
np
cho
cell
viral
protein
selfassembl
vlp
anim
experi
show
hantaviru
vlp
elicit
compar
antibodi
respons
inactiv
vaccin
enhanc
activ
cell
howev
protein
necessari
vlp
format
rodrigo
acuna
et
al
show
gn
gc
coexpress
gn
gc
mammalian
cell
assembl
vlp
suggest
np
protein
necessari
vlp
assembl
acuna
et
al
vlp
member
bunyavirida
famili
also
form
gn
gc
coexpress
overbi
et
al
mandel
et
al
two
human
pathogen
crimeancongo
hemorrhag
fever
viru
cchfv
sever
fever
thrombocytopeniasyndrom
viru
sftsv
seriou
health
threat
avail
vaccin
specif
therapeut
method
zhou
et
al
report
express
np
cchfv
use
baculoviru
express
system
yield
vlp
zhou
et
al
howev
immunogen
protect
efficaci
vlp
report
although
cchfv
sftsv
vlp
vaccin
report
studi
virus
famili
indic
express
viral
protein
yield
vlp
new
strategi
could
use
develop
vaccin
cchfv
sftsv
filovirus
envelop
nonseg
negativestrand
rna
virus
famili
genera
ebolaviru
marburgviru
filovirus
notabl
high
mortal
human
effect
vaccin
treatment
avail
matrix
protein
major
structur
protein
previou
data
show
contain
necessari
inform
assembl
bud
filoviru
vlp
although
sole
express
result
poor
vlp
product
warfield
aman
ebola
virus
contain
speci
bundibugyo
ebolaviru
bdbv
zair
ebolaviru
ebov
reston
ebolaviru
restv
sudan
ebolaviru
sudv
forest
ebolaviru
tafv
singh
et
al
bdbv
ebov
restv
caus
pandem
africa
restv
infect
found
asia
pathogen
lethal
case
report
ebov
etiolog
agent
ebola
outbreak
west
africa
baiz
et
al
ebov
vlp
vaccin
studi
sever
year
warfield
et
al
cotransfect
ebola
glycoprotein
gp
cell
viral
protein
selfassembl
particl
morpholog
similar
wildtyp
viru
ebov
vlp
highli
immunogen
vitro
vivo
ebov
vlp
effici
induc
matur
activ
secret
cytokin
chemokin
ebov
vlpvaccin
mice
exhibit
b
cell
activ
produc
high
level
ebovspecif
antibodi
vlp
also
activ
cell
ebov
vlp
could
also
protect
mice
lethal
challeng
warfield
et
al
ebov
vlp
also
produc
insect
cell
express
gp
baculoviru
express
system
result
vlp
also
effect
protect
mice
lethal
ebov
challeng
warfield
et
al
ebov
vlp
product
insect
cell
high
yield
vlp
show
potenti
develop
effect
ebov
vaccin
marburgviru
genu
speci
lake
victoria
marburg
viru
singl
protein
gener
vlp
viru
effici
vlp
gener
lower
follow
coexpress
protein
especi
gp
np
significantli
promot
format
bud
virion
warfield
aman
previou
data
show
coexpress
gp
without
np
mammalian
insect
cell
yield
similar
particl
morpholog
similar
nativ
virion
swenson
et
al
warfield
et
al
guinea
pig
vaccin
marburg
vlp
produc
mammalian
cell
elicit
abund
marvspecif
antibodi
neutral
antibodi
marv
vlp
stimul
dendrit
cell
differenti
promot
tcell
prolifer
complet
protect
guinea
pig
marv
infect
warfield
aman
vlp
protect
rodent
viru
infect
also
protect
nonhuman
primat
nhp
level
marvspecif
antibodi
vlpvaccin
monkey
increas
quickli
first
vaccin
peak
third
vaccin
warfield
aman
high
pathogen
avian
influenza
hpai
highli
contagi
highli
lethal
infecti
diseas
circul
bird
poultri
hpai
mainli
caus
influenza
viru
swayn
suarez
influenza
viru
belong
orthomyxovirida
famili
virus
orthomyxovirida
famili
negativesens
singlestrand
segment
rna
genom
genera
famili
includ
influenza
b
c
thogotoviru
isaviru
new
genu
quaranilviru
lvov
et
al
influenza
viru
envelop
lipid
membran
deriv
host
membran
hemagglutinin
ha
neuraminidas
na
major
surfac
glycoprotein
viral
membran
repres
main
epitop
matrix
gene
encod
two
protein
protein
involv
viral
bud
protein
transmembran
homotetramer
proton
ion
channel
involv
viru
uncoat
follow
entri
protein
target
univers
vaccin
design
extern
region
highli
conserv
human
influenza
virus
tradit
influenza
vaccin
eggbas
inact
vaccin
strategi
limit
applic
hpai
viru
lethal
chick
embryo
vlpbase
vaccin
novel
approach
treat
hpai
mani
studi
conduct
develop
influenza
vlp
vaccin
kang
et
al
although
vaccin
current
avail
influenza
vlp
construct
coexpress
ha
orand
na
protein
buonaguro
et
al
hpai
vlp
gener
insect
cell
bright
et
al
mammalian
cell
schmeisser
et
al
plant
vlp
produc
plant
protect
ferret
lethal
challeng
describ
data
phase
clinic
studi
show
plantproduc
vaccin
safe
vaccin
ferret
detect
hi
antibodi
vlp
vaccin
also
induc
detect
crossreact
hi
antibodi
ferret
clinic
studi
provid
evid
vlp
well
toler
human
hi
titer
rose
subject
second
dose
mg
group
respect
hi
antibodi
detect
sera
subject
placebo
group
vlp
contain
ha
na
express
insect
cell
baculoviru
express
system
could
also
protect
mice
lethal
challeng
offer
cross
protect
heterogen
viru
bright
et
al
sever
compani
includ
novavax
md
usa
develop
vlp
vaccin
produc
insect
cell
phase
clinic
studi
nipah
viru
niv
hendra
viru
hev
belong
paramyxovirida
famili
envelop
rna
virus
consist
membran
deriv
host
cell
matrix
protein
glycoprotein
f
g
embed
membran
paramyxoviru
matrix
protein
local
cellular
membran
express
infect
cell
recruit
glycoprotein
membran
glycoprotein
assembl
bud
membran
matrix
protein
report
main
drive
forc
particl
bud
scission
harrison
et
al
paramyxoviru
vlp
assembl
follow
coexpress
viral
matrix
protein
glycoprotein
niv
vlp
produc
cell
line
cotransfect
plasmid
encod
niv
g
f
protein
walpita
et
al
newcastl
diseas
viru
ndv
use
vector
express
niv
protein
cell
anim
test
show
nip
vlpvaccin
mice
produc
abund
nivspecif
antibodi
mount
strong
activ
cell
reaction
neutral
antibodi
also
detect
nip
vlpvaccin
pig
cell
detect
kong
et
al
vlp
paramyxovirida
virus
respiratori
syncyti
viru
rsv
construct
preclin
studi
result
promis
mcginn
et
al
studi
report
hendra
viruslik
particl
paramyxoviru
specul
hev
vlp
similarli
produc
calicivirida
famili
noroviru
nov
common
caus
agent
nonbacteri
gastroenter
human
member
noroviru
genu
calicivirida
famili
patel
et
al
nov
affect
peopl
age
respons
epidem
viral
gastroenter
adult
nov
singlestrand
positivesens
rna
genom
encod
major
structur
protein
minor
capsid
protein
viral
particl
demonstr
amorph
surfac
structur
nm
size
noroviru
genu
divid
genogroup
gigvi
divid
differ
genotyp
base
greater
pairwis
differ
amino
acid
sequenc
capsid
protein
ramani
et
al
virus
genogroup
known
infect
human
nov
genogroup
genotyp
current
circul
wide
herbstkralovetz
et
al
lack
vitro
cultiv
method
limit
develop
tradit
vaccin
moor
et
al
make
vlp
attract
candid
vaccin
result
sever
studi
demonstr
immunogen
safeti
nov
vlp
deliv
oral
intranas
rout
express
recombin
nov
capsid
protein
insect
plant
scotti
rybicki
mammalian
cell
harrington
et
al
yield
vlp
morpholog
antigen
similar
nativ
virion
preclin
mous
data
show
vlp
induc
humor
mucos
immun
deliv
oral
intranas
parenter
rout
phase
clinic
studi
ball
et
al
assess
safeti
immunogen
vlp
deliv
oral
ball
et
al
subsequ
studi
efficaci
intranas
administ
vlp
evalu
drypowd
formul
baculovirusderiv
vlp
adjuv
monophosphoryl
lipid
mucoadher
chitosan
test
well
toler
sever
advers
effect
show
dosedepend
increas
serum
antibodi
titer
elkamari
et
al
data
studi
bival
multival
vlp
candid
vaccin
adult
volunt
show
multival
vlp
vaccin
induc
broad
antibodi
respons
multipl
epitop
vaccin
nonvaccin
nov
strain
lindesmith
et
al
vlp
also
develop
promis
candid
vaccin
nov
infect
shown
efficaci
proofofconcept
human
experiment
infect
model
atmar
et
al
coronavirus
envelop
rna
virus
caus
acut
persist
infecti
human
anim
human
sever
acut
respiratori
syndrom
coronaviru
sarscov
merscov
major
human
coronavirus
caus
sever
human
ill
sarscov
identifi
outbreak
occur
china
recent
mer
emerg
infecti
diseas
first
report
saudi
arabia
caus
subsequ
outbreak
south
korea
ill
caus
merscov
member
betacoronaviru
genu
coronavirida
famili
virion
coronaviru
roughli
spheric
averag
diamet
rang
nm
cov
particl
compris
structur
protein
spike
protein
envelop
protein
e
membran
protein
nucleocapsid
protein
n
experi
sar
vlp
show
express
sarscov
viral
protein
e
baculoviru
lead
format
smooth
particl
without
spike
wherea
coexpress
e
yield
sar
vlp
mortola
roy
lu
et
al
found
mucos
system
immun
sar
vlp
produc
use
baculoviru
express
system
result
strong
igg
secret
iga
respons
sar
vlp
also
activ
dc
elicit
cellular
immun
respons
bai
et
al
lu
et
al
flavivirida
virus
singlestrand
positivesens
rna
virus
virion
spheric
nm
diamet
lipid
envelop
deriv
host
cell
membran
viral
genom
encod
structur
protein
core
protein
c
envelop
protein
e
membran
glycoprotein
protein
e
glycoprotein
function
fusion
protein
major
target
neutral
antibodi
schweitzer
et
al
protein
translat
immatur
form
prm
follow
cleavag
cellular
enzym
furin
develop
protein
matur
virion
tickborn
enceph
tbe
seriou
viral
diseas
caus
virus
flavivirida
famili
central
european
enceph
cee
viru
russian
springsumm
enceph
rsse
viru
inactiv
tbeviru
vaccin
current
avail
tbevlp
vaccin
avail
vlp
mani
flavivirus
dengu
fever
viru
denv
zhang
et
al
japanes
enceph
viru
jev
yamaji
et
al
exist
prm
protein
e
mediat
assembl
bud
flavivirus
previou
studi
provid
evid
prm
e
selfassembl
morpholog
similar
particl
protein
e
without
prm
form
vlp
du
et
al
denv
etiolog
agent
dengu
serotyp
denv
denv
vlp
studi
sever
system
mammalian
cell
pichia
pastori
insect
cell
e
coli
express
viral
protein
prm
e
mani
et
al
studi
show
evid
denv
vlp
stimul
immun
mice
produc
abund
neutral
antibodi
elicit
strong
cell
respons
zhang
et
al
mani
et
al
report
denv
e
protein
alon
form
vlp
result
vlp
good
immunogen
elicit
strong
specif
antibodi
respons
mani
et
al
denv
vlp
also
good
antigen
antibodi
detect
patient
sera
holm
et
al
chikungunya
fever
viru
chikv
arthropodborn
viru
transmit
human
mosquito
caus
sever
diseas
whose
common
symptom
fever
joint
pain
stapl
et
al
chikv
member
alphaviru
genu
togavirida
famili
viru
particl
consist
icosahedr
nucleocapsid
envelop
deriv
host
cell
membran
nucleocapsid
compos
copi
coat
protein
c
nm
diamet
envelop
contain
heterodim
compos
glycoprotein
chikv
vlp
produc
transfect
viral
protein
gene
ce
e
cell
vaccin
potenti
vlp
deriv
transfect
cell
demonstr
rodent
nhp
immunolog
experi
show
kind
vlp
elicit
specif
antibodi
neutral
antibodi
respons
immun
anim
vlp
approv
phase
clinic
trial
akahata
et
al
attempt
produc
chikv
vlp
use
baculoviru
express
system
report
specif
neutral
antibodi
respons
elicit
chikv
vlp
produc
use
baculoviru
express
system
equal
vlp
produc
mammalian
cell
system
could
complet
protect
guinea
pig
lethal
challeng
metz
et
al
infecti
diseas
alway
big
threat
human
health
advanc
biolog
medic
scienc
effort
understand
pathogen
prevent
infect
need
increas
vlp
repres
new
approach
develop
vaccin
virus
although
reach
market
vlpbase
vaccin
emerg
virus
current
avail
first
reason
lack
knowledg
regard
new
emerg
virus
secondli
good
anim
model
avail
infect
virus
test
vaccin
includ
common
vaccin
vlp
third
purif
technolog
vlp
main
limit
licens
vaccin
vlp
express
use
differ
express
system
vlp
often
contamin
residu
host
cell
compon
lipid
nucleic
acid
protein
may
stimul
immun
respons
result
major
safeti
concern
effici
technolog
explor
may
contribut
vlp
product
purif
promot
use
vlp
novel
vaccin
control
emerg
virus
success
hbv
hpv
vlp
vaccin
encourag
explor
possibl
develop
vlp
vaccin
variou
virus
date
vlp
repres
differ
viru
famili
develop
zeltin
tabl
summar
vlp
differ
viru
famili
construct
repres
vlp
sinc
hpv
vlp
vaccin
approv
sale
vlp
vaccin
licens
thereaft
although
mani
test
anim
research
great
expect
sever
vlp
vaccin
base
posit
result
clinic
trial
season
influenza
vlp
khurana
et
al
et
al
norwalk
vlp
vaccin
herbstkralovetz
et
al
hope
vlp
vaccin
may
approv
near
futur
